VFVanessa Felice

Vanessa Felice

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vanessa Felice has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 102. Elucidating the genomic landscape of Prostate Adenocarcinoma through whole genome and transcriptome sequencing

    by Marilena Melas, Heather Geiger, Sowmya T. Srinivasa, Saurav Guha, Vanessa Felice, Lena Fielding, Amanda Thomas-Wilson, Ashley Wilson, Theresa MacDonald, Ryan Smith, et al.

  • Open Access

    Abstract 757: Clinical interpretation and utility of whole genome and whole transcriptome sequencing for precision oncology

    by Kazimierz O. Wrzeszczynski, Heather Geiger, Sowmya T. Srinivasa, Marilena Melas, Valisha Shah, Vanessa Felice, Luisa Suarez, Endre Hegedus, Shruti Phadke, Saurav Guha, et al.

    The New York Genome Center CLIA laboratory has been providing New York State approved molecular diagnostic whole genome and whole transcriptome sequencing (WGTS) since October 2018. Indications for testing are cancers (solid tumors or hematological malignancies) where a mutational profile from multiple genes would be informative for disease stratification, prognosis, treatment options or alternative treatments or clinical trials. Germline analysis for ACMG designated cancer predisposition variants also is performed for consented patients. To date we have provided clinical next generation sequencing (NGS) genomic profile reports for 139 oncological cases from 31 different cancer types including GBM (41 cases), Pancreas (17), CRC (15), Lung (8) and others. The clinical interpretation of WGTS data of molecular tumor markers from NGS encompasses automated variant calling tools with human interpretation. The final mostly manual review of data is intensive, involving highly trained scientists engaged in substantial literature review and interpretation for each case alongside pathologists, molecular geneticists, and treating oncologists. We first present the technical challenges of validating a WGTS oncological diagnostic assay for appropriate clinical grade accuracy and sensitivity acceptable for patient care. We then present case studies illustrating the varying degree of tumor profiling and analysis outlining the current clinical utility and challenges of precision oncology medicine and therapeutic associations from sequencing of cancer patient tumors. We conclude with a previously unreported summary of therapeutic actionability derived from WGTS for all cancer cases sequenced at NYGC. We show that 28% percent of all samples in our cohort contain a tier 1 variant but additional second line therapies (or off-label drugs) can be considered for over 75% of WGTS sequenced cancer patients. Our case studies being in both solid tumor and hematological cancers illustrate the variability in sequencing data and the individual patient specificities in each interpretation of clinical findings. We show how NGS sequencing can offer multiple treatment outcomes when combining all genomic aberrations (copy number, structural variants and SNV/indels) found in a subtype of prostate cancer. We present hematological malignancies that show how certain DNA mutations point to RNA aberrations leading to therapeutic associations. In pancreatic cancer we present how a unique alteration in BRAF can lead to second line treatment with clinical benefit. We therefore demonstrate that more complete NGS assays those examining both the whole genome and transcriptome have added value in precision oncology practice enabling to find second-line treatment options or alternative therapeutic options when primary approaches fail or are not identified following a targeted sequencing approach. Citation Format: Kazimierz O. Wrzeszczynski, Heather Geiger, Sowmya T. Srinivasa, Marilena Melas, Valisha Shah, Vanessa Felice, Luisa Suarez, Endre Hegedus, Shruti Phadke, Saurav Guha, Dina Manaa, Dino Robinson, Lena Fielding, Vaidehi Jobanputra. Clinical interpretation and utility of whole genome and whole transcriptome sequencing for precision oncology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 757.

  • Top Cited Papers

    Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs

    by Kevin Hadi, Xiaotong Yao, Julie M. Behr, Aditya Deshpande, Charalampos Xanthopoulakis, Huasong Tian, Sarah Kudman, Joel Rosiene, Madison Darmofal, Joseph DeRose, et al.


  • Open Access

    Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer

    by Kazimierz O. Wrzeszczynski, Vanessa Felice, Avinash Abhyankar, Lukasz Kozon, Heather Geiger, Dina Manaa, Ferrah London, Dino Robinson, Xiaolan Fang, David Lin, et al.


  • Open Access

    Mechanisms of pigmentation loss in subterranean fishes

    by Vanessa Felice, Maria Aparecida Visconti, Eleonora Trajano

    Troglobitic (exclusively subterranean) organisms usually present, among their apomorphies related to the subterranean life (troglomorphisms), the regression of eyes and melanic pigmentation. The degree of regression varies among species, from a slight reduction to the complete loss of eyes and dark pigmentation, without a taxonomic correlation. While mechanisms of eye reduction have been intensively investigated in some troglobites such as the Mexican blind tetra characins, genus Astyanax, and the European salamander, Proteus anguinus, few studies have focused on pigmentation. The Brazilian subterranean ichthyofauna distinguishes not only by the species richness (23 troglobitic fishes so far known) but also by the variation in the degree of reduction of eyes and pigmentation. This study focused on Brazilian fishes completely devoid of melanic pigmentation: the characiform Stygichthys typhlops (Characidae) and the siluriforms Ancistrus formoso (Loricariidae), Rhamdiopsis sp.1 (Heptapteridae; from caves in the Chapada Diamantina, Bahia) and Rhamdiopsis sp. 2 (cave in Campo Formoso, Bahia). In order to investigate if such depigmentation is the result of blockage in some step in the melanogenesis, in vitro tests of administration of L-DOPA were done, using caudal-fin fragments extracted from living fish. Except for Rhamdiopsis sp. 2, all the studied species were DOPA(+), i.e., melanin was synthesized after L-DOPA administration. This indicates these fish do have melanophores but they are unable to convert L-tyrosine to L-DOPA. On the other hand, Rhamdiopsis sp. 2, like the albino specimens of Trichomycterus itacarambiensis previously studied (which correspond to one third of the population), are DOPA(-), either because the block of melanin synthesis occurs downstream in melanogenesis, which is probably the case with T. itacarambiensis (monogenic system in view of the phenotypic discontinuity), or because the so-called albinos do no possess melanophores. The physiological loss in the ability to synthesize melanin, apparently caused by different genetic processes in DOPA(+) and in DOPA(-) fishes, may co-exist in subterranean populations with a decrease in the density of melanophores, as observed in the pigmented two thirds of T. itacarambiensis population, a morphological reduction apparently controlled by polygenic systems producing a continuous phenotypic variation.